Peek Mark, Moran Paul, Mendoza Nerissa, Wickramasinghe Dineli, Kirchhofer Daniel
Department of Physiology, Genentech Inc., South San Francisco, California 94080, USA.
J Biol Chem. 2002 Dec 6;277(49):47804-9. doi: 10.1074/jbc.M209778200. Epub 2002 Oct 7.
Hepatocyte growth factor (HGF), the ligand for the receptor tyrosine kinase c-Met, is composed of an alpha-chain containing four Kringle domains (K1-K4) and a serine protease domain-like beta-chain. Receptor activation by HGF is contingent upon prior proteolytic conversion of the secreted inactive single chain form (pro-HGF) into the biologically active two chain form by a single cleavage at the Arg(494)-Val(495) bond. By screening a panel of serine proteases we identified two new HGF activators, plasma kallikrein and coagulation factor XIa (FXIa). The concentrations of kallikrein and FXIa to cleave 50% (EC(50)) of (125)I-labeled pro-HGF during a 4-h period were 10 and 17 nm. Unlike other known activators, both FXIa and kallikrein processed pro-HGF by cleavage at two sites. Using N-terminal sequencing they were identified as the normal cleavage site Arg(494)-Val(495) and the novel site Arg(424)-His(425) located in the K4 domain of the alpha-chain. The identity of this unusual second cleavage site was firmly established by use of the double mutant HGF(R424A/R494E), which was completely resistant to cleavage by kallikrein and FXIa. Experiments with another mutant form, HGF(Arg(494) --> Glu), indicated that cleavage at the K4 site was independent of a prior cleavage at the primary, kinetically preferred Arg(494)-Val(495) site. The cleavage at the K4 site had no obvious consequences on HGF function, because it was fully capable of phosphorylating the c-Met receptor of A549 cells. This may be explained by the disulfide bond network in K4, which holds the cleaved alpha-chain together. In conclusion, the ability of plasma kallikrein and FXIa to activate pro-HGF in vitro raises the possibility that mediators of inflammation and blood coagulation may also regulate processes that involve the HGF/c-Met pathway, such as tissue repair and angiogenesis.
肝细胞生长因子(HGF)是受体酪氨酸激酶c-Met的配体,由一条含有四个kringle结构域(K1-K4)的α链和一个类似丝氨酸蛋白酶结构域的β链组成。HGF对受体的激活取决于先前通过在Arg(494)-Val(495)键处的单次切割将分泌的无活性单链形式(pro-HGF)蛋白水解转化为生物活性双链形式。通过筛选一组丝氨酸蛋白酶,我们鉴定出两种新的HGF激活剂,血浆激肽释放酶和凝血因子XIa(FXIa)。在4小时内切割50%(EC(50))的(125)I标记的pro-HGF所需的激肽释放酶和FXIa浓度分别为10和17 nM。与其他已知的激活剂不同,FXIa和激肽释放酶都通过在两个位点切割来处理pro-HGF。通过N端测序,它们被鉴定为正常切割位点Arg(494)-Val(495)和位于α链K4结构域中的新位点Arg(424)-His(425)。通过使用双突变体HGF(R424A/R494E),该异常的第二个切割位点的身份得以确定,该双突变体对激肽释放酶和FXIa的切割完全抗性。用另一种突变形式HGF(Arg(494) --> Glu)进行的实验表明,在K4位点的切割独立于在主要的、动力学上优先的Arg(494)-Val(495)位点的先前切割。在K4位点的切割对HGF功能没有明显影响,因为它完全能够磷酸化A549细胞的c-Met受体。这可能是由K4中的二硫键网络解释的,该网络将切割后的α链保持在一起。总之,血浆激肽释放酶和FXIa在体外激活pro-HGF的能力增加了炎症和血液凝固介质也可能调节涉及HGF/c-Met途径的过程(如组织修复和血管生成)的可能性。